December 3, 2024
Roche and COUR Pharmaceuticals Collaborate on Autoimmune Disease Treatment in Deal Worth Over $900 Million
Roche, COUR Pharmaceuticals, autoimmune disease, Genentech, antigen-specific immune tolerance platform, biotech collaboration
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros
Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership
Alligator Bioscience Cuts 70% of Workforce to Address Financial Challenges and Refocus on Pancreatic Cancer Research
Alligator Bioscience, layoffs, cost-cutting, pancreatic cancer research, financial constraints, biotech industry
Pragmatic Clinical Trials: Bridging the Gap Between Research and Real-World Practice
1. Pragmatic Clinical Trials, 2. Real-World Evidence, 3. Clinical Trial Design, 4. Effectiveness Research, 5. Healthcare Decision Making
Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset
Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024
Olema Secures $250 Million Funding for Pivotal Breast Cancer Trial Featuring Novartis’ Kisqali
Olema, Breast Cancer, Novartis, Kisqali, Pivotal Trial, Funding
Novartis Invests $1 Billion in PTC’s Huntington’s Disease Program
Novartis, PTC, Huntington’s disease, pharmaceutical investment, gene therapy
Sanofi Invests €1 Billion in Beijing to Enhance Insulin Production Capacity
Sanofi, insulin production, Beijing, investment, pharmaceutical industry